P Glycoprotein (Abcb1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
P-glycoprotein (ABCB1) is an ATP-dependent efflux transporter that pumps drugs and toxins out of cells. At the [blood-brain barrier](/entities/blood-brain-barrier), it prevents many therapeutic drugs from entering the brain, limiting treatment options for neurological diseases [1].
P Glycoprotein (Abcb1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
P-glycoprotein (ABCB1) is an ATP-dependent efflux transporter that pumps drugs and toxins out of cells. At the [blood-brain barrier](/entities/blood-brain-barrier), it prevents many therapeutic drugs from entering the brain, limiting treatment options for neurological diseases [1].
Structure
ABCB1 is a 1280 amino acid protein with:
Two transmembrane domains: Each with 6 transmembrane helices
Two nucleotide-binding domains (NBDs): Bind and hydrolyze ATP
Substrate-binding pocket: Recognizes diverse compounds
Domain Architecture
TM1-6----NBD1----TM7-12----NBD2
Each TMD: 6 transmembrane helices Each NBD: Walker A/B motifs for ATP binding
Mechanism of Action
ABCB1 uses the energy from ATP hydrolysis to transport substrates:
Substrate Binding: Drug binds to transmembrane domains
ATP Binding: Two ATP molecules bind to NBDs
Conformational Change: Substrate is released on the opposite side
ATP Hydrolysis: Resets the transporter
Normal Function
Blood-Brain Barrier
ABCB1 is the main efflux transporter at the BBB:
Efflux Pump: Actively pumps drugs out of the brain
Protection: Prevents toxins from entering the CNS
Homeostasis: Maintains brain microenvironment
Tissue Distribution
Highest expression at the blood-brain barrier
Also expressed in liver, kidney, intestine
Protects sanctuary sites from toxins
Role in Neurodegeneration
Alzheimer's Disease
ABCB1 function declines with age
May contribute to [amyloid-beta](/proteins/amyloid-beta) clearance
Affects drug delivery for AD treatment [2]
Parkinson's Disease
Altered expression in PD brains
May affect levodopa pharmacokinetics
Contributes to treatment resistance
Epilepsy
Overexpression causes drug-resistant epilepsy
Major mechanism of antiepileptic drug resistance
Target for epilepsy treatment strategies
Brain Cancer
Contributes to chemotherapeutic drug resistance
Major obstacle to effective brain tumor treatment
Therapeutic Implications
Overcoming Drug Resistance
ABCB1 inhibitors: Can enhance drug delivery but have toxicity
[Pardridge, Blood-brain barrier drug delivery (2019)](https://doi.org/10.1038/s41582-019-0182-4). Nature Reviews Neurology.
Background
The study of P Glycoprotein (Abcb1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.